Influenza and Other Respiratory Viruses最新文献

{"title":"Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants","authors":"María Luz García-García,&nbsp;Patricia Alonso-López,&nbsp;Sonia Alcolea,&nbsp;M. Arroyas,&nbsp;Francisco Pozo,&nbsp;Inmaculada Casas,&nbsp;Maria Iglesias-Caballero,&nbsp;Rocío Sánchez-León,&nbsp;Jara Hurtado-Gallego,&nbsp;Cristina Calvo","doi":"10.1111/irv.70105","DOIUrl":"https://doi.org/10.1111/irv.70105","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare the clinical and virological characteristics of respiratory infections in hospitalized infants before and after nirsevimab introduction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We carried out a prospective study across two hospitals in Madrid during the 2022–2023 and 2023–2024 epidemic seasons. The study included infants under 12 months of age that were hospitalized with lower respiratory tract infections (LRTIs). Clinical, epidemiological, and virological data were analyzed and compared between the periods before and after the introduction of nirsevimab, as well as according to whether the infants had received this preventive treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 669 infants were included: 480 from October 2022 to March 2023 (S1) and 189 from October 2023 to March 2024 (S2). Respiratory infection–related admissions decreased by 62.5% in S2, with a 74.5% reduction in ICU admissions. RSV-related admissions decreased by 78%, HMPV by 36.6%, and adenovirus by 69.5%. Infants in S2 were older (<i>p</i> = 0.001) and had shorter hospital stays (<i>p</i> &lt; 0.001) than in S1. Of 63 (33%) infants in S2 who received nirsevimab, 11 (17%) were diagnosed with RSV. High-flow oxygen use was less frequent among RSV patients treated with nirsevimab (<i>p</i> = 0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need for intensive care, especially in RSV-infected infants but also in HMPV and adenovirus-infected infants.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Improved Rapid and Sensitive Long Amplicon Method for Nanopore-Based RSV Whole-Genome Sequencing","authors":"Xiaomin Dong,&nbsp;Steven Edwards,&nbsp;Yi-Mo Deng,&nbsp;Clyde Dapat,&nbsp;Arada Hirankitti,&nbsp;Rachel Wordsworth,&nbsp;Paul Whitney,&nbsp;Rob Baird,&nbsp;Kevin Freeman,&nbsp;Andrew J. Daley,&nbsp;Ian G. Barr","doi":"10.1111/irv.70106","DOIUrl":"https://doi.org/10.1111/irv.70106","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Whole-genome sequencing (WGS) provides critical insights into the respiratory syncytial virus (RSV) transmission and any emerging mutations that could impair the efficacy of monoclonal antibodies or vaccines that have been recently licenced for clinical use worldwide. However, the ability to sequence RSV genomes at large scale is limited by expensive and time-consuming sequencing methods. Oxford Nanopore Technology (ONT) offers significant improvements in next generation sequencing (NGS) both in turnaround time and cost, compared with other platforms for viral WGS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We have developed and modified an RSV long amplicon-based WGS protocol for the ONT platform using a one-step multiplex RT-PCR assay and the rapid barcoding kit. One hundred thirty-five RSV positive Australian clinical specimens (91 RSV-A and 44 RSV-B) sampled in 2023 with cycle threshold (Ct) values between 14 to 35 were tested in this study. This ONT workflow was compared with other recent RSV WGS amplification assays based on short amplicons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A PCR amplicon clean-up step prior to library preparation significantly improved WGS result for samples with poor amplicon generation, but it is not necessary or beneficial for ones that generated high concentrations of amplicons. Overall, a success rate of 85.9% was achieved for WGS. This method performed as well as the more complex short amplicon methods in terms of genome coverage and sequencing depth.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The workflow described here was highly successful in generating RSV WGS on ONT platform and had improved turnaround times and excellent results with RSV clinical samples with Ct values up to 30.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019","authors":"Caihua Liang,&nbsp;Aleksandra Polkowska-Kramek,&nbsp;Caroline Lade,&nbsp;Lea J. Bayer,&nbsp;Robin Bruyndonckx,&nbsp;Bennet Huebbe,&nbsp;Worku Biyadgie Ewnetu,&nbsp;Pimnara Peerawaranun,&nbsp;Maribel Casas,&nbsp;Thao Mai Phuong Tran,&nbsp;Gordon Brestrich,&nbsp;Christof von Eiff,&nbsp;Bradford D. Gessner,&nbsp;Elizabeth Begier,&nbsp;Gernot Rohde","doi":"10.1111/irv.70097","DOIUrl":"https://doi.org/10.1111/irv.70097","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>RSV incidence in adults is frequently underestimated due to non-specific symptomatology, limited standard-of-care testing, and lower test sensitivity compared to infants. We conducted a retrospective observational study to estimate RSV-attributable incidence of specific types of cardiorespiratory hospitalizations among adults in Germany between 2015 and 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Information on hospitalizations and the number of people at risk of hospitalization (denominator) was gathered from a Statutory Health Insurance database. A quasi-Poisson regression model accounting for periodic and aperiodic time trends and virus activity was fitted to estimate the RSV-attributable incidence rate (IR) of four specific cardiovascular hospitalizations (arrhythmia, ischemic heart diseases, chronic heart failure exacerbations, and cerebrovascular diseases) and four specific respiratory hospitalizations (influenza/pneumonia, bronchitis/bronchiolitis, chronic lower respiratory tract diseases, and upper respiratory tract diseases).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The estimated RSV-attributable IRs of hospitalizations generally increased with age. Among estimated cardiovascular hospitalizations in adults aged ≥ 60 years, arrhythmia and ischemic heart diseases accounted for the highest incidence of RSV-attributable events, followed by chronic heart failure exacerbation, with annual IR ranges of 157–260, 133–214, and 105–169 per 100,000 person-years, respectively. The most frequent RSV-attributable respiratory hospitalizations in adults aged ≥ 60 years were estimated for chronic lower respiratory tract diseases and bronchitis/bronchiolitis, with annual IR ranges of 103–168 and 77–122 per 100,000 person-years, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>RSV causes a considerable burden of respiratory and cardiovascular hospitalizations in adults in Germany, similar to other respiratory viruses (e.g., influenza and SARS-CoV-2). This highlights the need to implement effective prevention strategies, especially for older adults.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"General Population and Healthcare Professionals' Level of Knowledge of the Burden and Prevention of Respiratory Syncytial Virus in France","authors":"Joshua Puel,&nbsp;Katia Sosnowiez,&nbsp;Robin Stephan,&nbsp;Albert Sotto,&nbsp;Paul Loubet","doi":"10.1111/irv.70103","DOIUrl":"https://doi.org/10.1111/irv.70103","url":null,"abstract":"&lt;p&gt;Respiratory viral infections are both common and potentially severe. Their incidence and microbial diversity have risen, with notable changes in the last decade primarily driven by greater awareness and testing capabilities [&lt;span&gt;1-4&lt;/span&gt;]. Pneumonia resulting from these pathogens is more common and severe in the elderly and those with comorbidities, particularly in immunocompromised individuals [&lt;span&gt;5&lt;/span&gt;]. Due to the development of new treatments for cancer and autoimmune diseases, the number of patients at high risk of severe infections has increased significantly [&lt;span&gt;6, 7&lt;/span&gt;]. This trend highlights the need for global and targeted public health prevention measures, including developing new vaccines and enhancing existing ones. However, even among those most at risk [&lt;span&gt;8&lt;/span&gt;], inadequate vaccination coverage is currently a critical issue.&lt;/p&gt;&lt;p&gt;Respiratory syncytial virus (RSV) is an excellent example of a pathogen that is (i) becoming increasingly known of being burdensome on the healthcare system with its high morbidity rate in elderly, immunocompromised patients and those with chronic conditions, (ii) having new preventive tools available. Three vaccines, one monovalent adjuvanted protein vaccine (RSVpre-F3), one bivalent nonadjuvanted protein vaccine (RSVpre-F), and one monovalent mRNA vaccine (mRNA-1345) have been granted marketing authorization by the Food and Drug Administration and European Medical Agency in adults aged 60 years and over in 2023 and 2024. Furthermore, the RSVpre-F has been approved in pregnant women to protect newborns. These vaccines are recommended for people of different ages and with various risk factors worldwide. In July 2024, the French NITAG (National Immunization Technical Advisory Group) recommended RSV vaccination for those over 75 years, those over 65 with a chronic cardiac or respiratory condition, and pregnant women. Additionally, nirsevimab, a long-acting monoclonal antibody for RSV, has been available and recommended in France for infants in their first year of life since winter 2023/2024, with the option of maternal immunization left to the parents. Both nirsevimab and maternal RSVpre-F have received reimbursement approval. RSV vaccines for older adults are still pending reimbursement.&lt;/p&gt;&lt;p&gt;More than ever, we must provide clear and appropriate information to these populations regarding viral respiratory infections and ways to prevent them.&lt;/p&gt;&lt;p&gt;This study aimed to provide an overview of the knowledge of a broad sample of French individuals from the general population and their caregivers concerning RSV infection and prevention.&lt;/p&gt;&lt;p&gt;Our study had the advantage of surveying a large representative sample of French people, isolating an at-risk population, and examining the knowledge of HCPs.&lt;/p&gt;&lt;p&gt;On the eve of the large-scale commercialization of vaccines against RSV, the issue of vaccine acceptance is more relevant than ever.&lt;/p&gt;&lt;p&gt;Our findings among the French population are","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Viral Interference in Shaping RSV Epidemics Following the 2009 H1N1 Influenza Pandemic","authors":"Ke Li,&nbsp;Deus Thindwa,&nbsp;Daniel M. Weinberger,&nbsp;Virginia E. Pitzer","doi":"10.1111/irv.70111","DOIUrl":"https://doi.org/10.1111/irv.70111","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Disruptions in respiratory syncytial virus (RSV) activity were observed in different countries following the 2009 influenza pandemic. Given the limited use of non-pharmaceutical interventions, these disruptions provide an opportunity to probe viral interference due to the out-of-season epidemics. The objectives of the study are twofold: to characterize atypical RSV activity in the United States (US) and to explore the mechanisms underlying changes in RSV epidemics following the pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Laboratory-confirmed RSV cases across 10 US regions from June 2007 to July 2019 were analyzed. A dynamic time warping method was used to characterize RSV activity in different seasons. A two-pathogen model was constructed to explore viral interference mechanisms. A sampling–importance–resampling method was applied to estimate the effects of viral interference.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that RSV activity was reduced following the influenza pandemic in the 2009/10 season across all regions in the US. By contrast, we found an enhanced but delayed RSV epidemic across the US in the 2010/11 season. Using a mathematical model, we explored three potential viral interference mechanisms that could explain the change of RSV activity following the pandemic. The pandemic influenza may interfere with RSV to reduce susceptibility to RSV coinfection, or shorten the RSV infectious period, or decrease RSV infectivity in co-infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study provides statistical evidence for atypical RSV seasons following the influenza pandemic in the US and sheds light on viral interference mechanisms affecting RSV epidemics, offering a model-fitting framework for analyzing surveillance data at the population level.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Shifts in Children Respiratory Pathogens in Shenzhen, China: A Comparative Analysis Before and After the Relaxation of COVID-19 Non-Pharmaceutical Interventions","authors":"Heping Wang,&nbsp;Yuping Guo,&nbsp;Rongjun Wang,&nbsp;Zihao Liu,&nbsp;Li Li,&nbsp;Yuzheng Li,&nbsp;Yanmin Bao,&nbsp;Wenjian Wang","doi":"10.1111/irv.70114","DOIUrl":"https://doi.org/10.1111/irv.70114","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The COVID-19 pandemic and associated non-pharmaceutical interventions significantly altered the epidemiology of respiratory pathogens. This study aimed to evaluate the changes in the prevalence and distribution of respiratory pathogens among children with acute respiratory infections (ARIs) before and after the relaxation of COVID-19 restrictions in Shenzhen, China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study enrolled hospitalized children with ARIs in Shenzhen Children's Hospital during the COVID-19 epidemic and those post-epidemic period. Demographic data of the patients enrolled were retrieved from the Shenzhen Children's Hospital electronic patient dossiers. Nasopharyngeal swabs were collected and detected for 11 pathogens, and epidemiological trends were analyzed by age, season, and pathogen distribution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 40,174 children with ARIs were enrolled, including 14,816 during the COVID-19 epidemic and 25,358 in the post-epidemic period. Hospital admissions for ARIs increased by 71.2% in the post-epidemic period. The median age of patients rose from 27 to 47 months. Pathogen detection rates increased significantly from 59.3% during epidemic period to 73.0% in post-epidemic period (<i>p</i> &lt; 0.001), with co-detection (≥ 2 pathogens) rising from 10.5% to 21.2%. The dominant pathogens shifted from HRV, RSV, and HPIV during COVID-19 epidemic to HRV, MP, and RSV in the post-epidemic. Notably, MP detection rates surged from 1.69% to 20.87%, while RSV and HPIV peaks were replaced by MP and HMPV in winter.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The relaxation of COVID-19 non-pharmaceutical interventions led to a significant rebound in ARIs among children, with altered pathogen dominance and increased co-detection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70114","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 Anti-S an Anti-N IgG Seropositivity in Children and Young People (1–24 Years) According to HIV Status in Lomé (Togo) in 2022","authors":"Yao Rodion Konu,&nbsp;Florence Damond,&nbsp;I. Wone Oumarou Adama,&nbsp;Valentine Marie Ferré,&nbsp;Alassane Ouro-médéli,&nbsp;Ounoo Elom Takassi,&nbsp;Nina Dapam,&nbsp;Magnoulélén N'zonou,&nbsp;Ridwane Bawa-Kawte,&nbsp;Martin Kouame Tchankoni,&nbsp;Arnold Junior Sadio,&nbsp;Fatoumata Binta Tidiane Diallo,&nbsp;Claver Anoumou Dagnra,&nbsp;Charlotte Charpentier,&nbsp;Didier Koumavi Ekouevi","doi":"10.1111/irv.70112","DOIUrl":"https://doi.org/10.1111/irv.70112","url":null,"abstract":"<p>We aimed to estimate SARS-CoV-2 seropositivity among children and young people in Lomé, Togo, according to HIV status. A multicenter comparative cross-sectional study was conducted, and 636 participants were included (41.8% living with HIV). Anti-S (88.7% vs. 89.1%) and anti-N (41.6% vs. 39.5%) IgG seropositivity were comparable in both groups. These data suggest no increased COVID-19 susceptibility in children and young people with HIV.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70112","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living With School-Aged Children and the Risk of Absenteeism Among Healthcare Workers During the Twindemic of COVID-19 and Influenza","authors":"Shohei Yamamoto,&nbsp;Tetsuya Mizoue,&nbsp;Maki Konishi,&nbsp;Kumi Horii,&nbsp;Wataru Sugiura,&nbsp;Norio Ohmagari","doi":"10.1111/irv.70100","DOIUrl":"https://doi.org/10.1111/irv.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The impact of the simultaneous circulation of COVID-19 and seasonal influenza, termed the “Twindemic,” on absenteeism among healthcare workers (HCWs), particularly those with children, remains unclear. We aimed to investigate the associations of living with school-aged children with the risk of SARS-CoV-2 and influenza infections and the risk of absenteeism due to own- or family-related COVID-19 or influenza events among HCWs during the Twindemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study followed 1473 HCWs at a tertiary hospital in Tokyo from December 2023 to March 2024. We tracked the incidence of SARS-CoV-2 and influenza infections and absenteeism due to COVID-19 or influenza-related family events. We estimated the hazard ratios (HRs) or incidence rate ratios (IRRs) of these outcomes across living arrangements, focusing on cohabitation with school-aged children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>HCWs living with younger school-aged children (≤ third grade of junior school) had a higher risk of SARS-CoV-2 and influenza infections, with HRs [95% confidence interval (CI)] of 1.90 [0.97–3.69] and 2.42 [1.04–5.66], respectively, compared with those living with cohabitants without school-aged children. Additionally, they showed a higher IRR [95% CI] for absenteeism due to family-related events (10.9 [4.88–24.5]), and their overall IRR [95% CI] of absenteeism due to own/family-related events was 3.76 [2.59–5.46].</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Twindemic has heightened absenteeism risks among HCWs with school-aged children, emphasizing the need for targeted support to help HCWs manage both their professional duties and family responsibilities during such challenging times.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019","authors":"Zirke Wiid,&nbsp;Caihua Liang,&nbsp;Robin Bruyndonckx,&nbsp;Lauren Mason,&nbsp;Aleksandra Polkowska-Kramek,&nbsp;Pimnara Peerawaranun,&nbsp;Mikel Esnaola,&nbsp;Worku Biyadgie Ewnetu,&nbsp;Somsuvro Basu,&nbsp;David Witcombe,&nbsp;Bradford D. Gessner,&nbsp;Elizabeth Begier","doi":"10.1111/irv.70092","DOIUrl":"https://doi.org/10.1111/irv.70092","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Respiratory syncytial virus (RSV) morbidity and mortality in adults are often underestimated due to nonspecific symptoms, limited standard-of-care testing and lower diagnostic testing sensitivity compared with children. To accurately evaluate the RSV disease burden among adults in Australia, we conducted a model-based study to estimate RSV-attributable cardiorespiratory hospitalisation incidence and mortality rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A quasi-Poisson regression model was used to estimate RSV-attributable cardiorespiratory, respiratory and cardiovascular events, using weekly hospitalisation and mortality data from 2010 to 2019, accounting for periodic and aperiodic time trends and viral activity and allowing for potential overdispersion. The time-series model compared the variability in confirmed RSV events alongside variability in all-cause cardiorespiratory events identified from ICD-10-AM codes to estimate the number of RSV-attributable events, including undiagnosed RSV-related events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RSV-attributable incidence of cardiorespiratory hospitalisations increased with age and was highest among adults ≥ 65 years (329.5–386.6 cases per 100,000 person-years), nine times higher than in adults 18–64 years. The estimated incidence of RSV-attributable respiratory hospitalisations in adults ≥65 years (219.7–247.8 cases per 100,000 person-years) was 35-fold higher than in adults 18–64 years. RSV-attributable deaths accounted for 4% to 6% of cardiorespiratory deaths in adults ≥ 65 years, with RSV-attributable mortality rates ranging from 65.6 to 77.6 deaths per 100,000 person-years and respiratory mortality rates ranging from 20.3 to 24.0 deaths per 100,000 person-years, both 70-fold higher than in adults 18–64 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study identified substantial RSV-associated morbidity and mortality among Australian adults and is the first study to report RSV-attributable mortality rates for Australia that account for untested events.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seasonal Influenza Vaccination in People who Have Contact With Birds","authors":"Amy Thomas,&nbsp;Suzanne Gokool,&nbsp;Harry Whitlow,&nbsp;Genevieve Clapp,&nbsp;Peter Moore,&nbsp;Richard Puleston,&nbsp;Louise E. Smith,&nbsp;Riinu Pae,&nbsp;Ellen Brooks-Pollock","doi":"10.1111/irv.70101","DOIUrl":"https://doi.org/10.1111/irv.70101","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Following the 2021–2022 avian influenza panzootic in birds and wildlife, seasonal influenza vaccines have been advised to occupationally high-risk groups to reduce the likelihood of coincidental infection in humans with both seasonal and avian influenza A viruses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We developed and launched a questionnaire aimed at poultry workers and people in direct contact with birds to understand awareness and uptake of seasonal influenza vaccination. We collected responses in-person at an agricultural trade event and online.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>The questionnaire was completed by 225 individuals from across the United Kingdom. The most commonly reported reason for vaccination was protection against seasonal influenza (82%, 63 of 77). Nearly, all individuals aged ≥65 years reported that the vaccine was recommended for them (24 of 28). There was no difference in recommendation for occupational groups. Most vaccinees were aged over 60 years (60%, 29 of 48); however, coverage was lower than expected in the ≥ 65 target group. Vaccination in those exposed to avian influenza was low (32%, 9 of 28). Not having enough time was the single most reported reason for not getting vaccinated in those intending to. Individuals unintending to be vaccinated perceived natural immunity to be better than receiving the vaccine as well as lack of awareness and time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings suggest that targeted campaigns in occupationally exposed groups need to be undertaken to improve communication of information and access to vaccine clinics. We recommend co-production methods to optimise this public health strategy for increased knowledge and future vaccine uptake.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}